Syndax Pharmaceuticals Inc Net Cash Provided by (Used in) Financing Activities in USD from 2016 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Syndax Pharmaceuticals Inc quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2016 to Q1 2025.
  • Syndax Pharmaceuticals Inc Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $930K, a 57.1% decline year-over-year.
  • Syndax Pharmaceuticals Inc annual Net Cash Provided by (Used in) Financing Activities for 2024 was $353M, a 33.8% increase from 2023.
  • Syndax Pharmaceuticals Inc annual Net Cash Provided by (Used in) Financing Activities for 2023 was $264M, a 53.3% increase from 2022.
  • Syndax Pharmaceuticals Inc annual Net Cash Provided by (Used in) Financing Activities for 2022 was $172M, a 45.4% increase from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Syndax Pharmaceuticals Inc Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $930K -$1.24M -57.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-05
Q1 2024 $2.17M -$306K -12.4% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-05
Q1 2023 $2.47M +$1.92M +344% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 $557K -$403K -42% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q1 2021 $960K -$54M -98.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 $55M +$26.6M +93.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q1 2019 $28.4M -$4.57M -13.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q1 2018 $33M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08

Syndax Pharmaceuticals Inc Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $353M +$89.2M +33.8% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-03
2023 $264M +$91.9M +53.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-03
2022 $172M +$53.8M +45.4% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-03
2021 $118M -$186M -61.1% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $304M +$276M +966% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $28.6M +$12.8M +81.6% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $15.7M -$60M -79.2% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-12
2017 $75.7M +$21.5M +39.7% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-05
2016 $54.2M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.